WP
CLYM

Woodline Partners’s Climb Bio CLYM Stock Holding History

Woodline Partners’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-22,192
Closed -$158K – 726
2024
Q2 		$158K Buy
+22,192
New +$148K ﹤0.01% 536
2022
Q4 		– Sell
-226,604
Closed -$732K – 858
2022
Q3 		$732K Sell
226,604
-146,764
-39% -$468K 0.01% 559
2022
Q2 		$1.13M Hold
373,368
– – 0.02% 503
2022
Q1 		$3.13M Hold
373,368
– – 0.05% 305
2021
Q4 		$3.9M Sell
373,368
-13,856
-4% -$207K 0.06% 316
2021
Q3 		$6.96M Buy
+387,224
New +$8M 0.11% 214

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Woodline Partners's CLYM Position: Q3 2024 in Review

Woodline Partners sold out of Climb Bio (CLYM) in Q3 2024, closing a stake of 22,192 shares — an estimated $158K sold.

Woodline Partners first reported a position in CLYM in Q3 2021 and held it in 6 quarters. The position peaked at $6.96M in Q3 2021. 71 funds tracked by Wall St. Rank hold CLYM as of Q3 2024.

  • Woodline Partners reported no remaining Climb Bio position as of Q3 2024 after selling out during the quarter.
  • Woodline Partners sold 22,192 Climb Bio shares in Q3 2024, an estimated $158K.
  • Woodline Partners first reported a position in Climb Bio in Q3 2021 and held it in 6 quarters.
  • Woodline Partners's Climb Bio position peaked at $6.96M in Q3 2021.
  • 71 funds tracked by Wall St. Rank held Climb Bio as of Q3 2024.

Based on Woodline Partners's 13F filing for Q3 2024, filed 14 Nov 2024.